摘要
目的:探讨人附睾分泌蛋白4(HE4)在血清及尿液中的表达水平及与血清糖类抗原癌抗原125(CA_(125))联合检测诊断卵巢癌的价值及其与卵巢癌临床病理特征的关系。方法:应用E LISA法检测41例卵巢癌、32例卵巢良性肿瘤、30例健康对照血清及尿液HE4含量,比较其单项及联合血清CA_(125)检测在卵巢癌诊断中的敏感性及特异性。结果:①卵巢癌组血清及尿液HE4含量与卵巢良性肿瘤组及健康对照组比较,差异均有统计学意义(P<0.05)。②卵巢癌组血清及尿液HE4含量在手术前后比较差异均有统计学意义(P<0.05)。③血清及尿液HE4含量子宫内膜样癌和浆液性腺癌均高于其他类型卵巢癌(P<0.05)。④血清及尿液HE4诊断卵巢癌的敏感性分别为58.5%和68.3%,特异性分别为83.9%和93.5%,两者间比较差异无统计学意义(P>0.05)。血清及尿液HE4联合血CA_(125)检查诊断卵巢癌的敏感性分别为85.4%和92.7%,特异性分别为85.5%和96.8%,两者间比较差异无统计学意义(P>0.05),尿液HE4联合CA_(125)检测的敏感性、特异性稍高。结论:卵巢癌患者血清及尿液HE4含量均高。尿液HE4联合血清CA_(125)检测可作为卵巢癌高危人群筛查及早期诊断的参考指标。
Objective：To study the expression of humanepididymis secretory protein4 （HE4） in serum and urine, and combined with serum carbohydrate antigen125 （CA12s） to diagnosis of ovarian cancer and the relationship with its clinical pathological characteristics. Methods：serum and urine HE4 and serum CA125 in 41 patients with ovarian cancer, 32 patients with ovarian benign tumor and 30 cases with healthy controls were detected by enzyme-linked immunosorbent assay technique. The sensitivity and specificity of the single and combined detection of urine and serum HE4 and serum CA125in the diagnosis of ovarian cancer were calculated and compared. Results：~The serum and urinary HE4 of patients with ovarian cancer before sur- gery were significantly higher than those of ovarian benign tumor and healthy controls（ P 〈 0.05）. （2）The ser- um and urinary HE4 of patients with ovarian cancer before surgery were significantly higher than those one week after operation （P〈0.05）. ~The serum and urinary HE4 in endometrioid carcinoma and serous cys- tadenocarcinoma were higher than other types of ovarian cancer（ P 〈0.05）. （4）The sensitivity of serum and urinary HE4 in ovarian cancer group was 58.5% and 68.3%, and the specificity was 83.9% and 93.5%, respectively（ P 〉0.05）. The sensitivity of serum and urinary HE4 combined with serum CA125 in ovarian cancer group was 85.4% and 92.7%, and the specificity was 85.5% and 96.8%, respectively（P〉0.05）. Conclusions：Serum and urinary HE4 increased in patients with ovarian cancer. The combined detection of urinary HE4 together with CA12s may be an indicator for high-risk population screening and early diagnosis of ovarian cancer.
出处
《实用妇产科杂志》
CAS
CSCD
北大核心
2014年第3期220-223,共4页
Journal of Practical Obstetrics and Gynecology
关键词
卵巢癌
人附睾分泌蛋白4
癌抗原125
酶联免疫吸附试验
Ovarian cancer
Humanepididymis secretory protein4
Cancer antigen 125
Enzyme-linkedimmunosorbent assay technique
